Lining up the acellular pertussis competition

WASHINGTON - Beyond the immediate spotlight put on North American Vaccine Inc.'s Certiva acellular pertussis vaccine, last week's meeting of the FDA's Vaccines and Related Biological Products Advisory Committee focused attention on the coming competition between similar vaccines manufactured by several companies.

The impetus for development of these products, which are combined with diphtheria and tetanus toxoids to form a DTaP vaccine, has come from the relatively high incidence of adverse effects associated with whole-cell vaccines. The side-effects have caused some countries to abandon universal vaccination programs and has limited compliance in other countries. Acellular pertussis

Read the full 960 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE